Skip to content

Individualized Automatic Target Coaching Message for Glycemic Management and Depressive Symptom

Feasibility and Acceptability of Individualized Automatic Target Coaching Message Based on the Metrics of Continuous Glucose Monitoring and Depressive Symptom

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06525454
Enrollment
18
Registered
2024-07-29
Start date
2024-08-07
Completion date
2024-09-30
Last updated
2024-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 1

Brief summary

This is a single-center, randomized, prospective, feasibility and acceptability trial in patients with type 1 diabetes. For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires. The control group will remain on their current treatment and will not receive any intervention. The purpose of this trial is to evaluate the feasibility and acceptability of the clinical application of automated, personalized coaching messages for glycemic management and depressive symptom in people with type 1 diabetes.

Interventions

BEHAVIORALPersonalized coaching messages for blood glucose and emotions

For six weeks, the intervention group will receive weekly personalized coaching messages for glycemic management based on blood data from continuous glucose monitors and bi-weekly personalized coaching messages for depression management based on depression questionnaires.

Sponsors

Samsung Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

1:2 ratio

Eligibility

Sex/Gender
ALL
Age
20 Years to 69 Years
Healthy volunteers
No

Inclusion criteria

* Patients who are determined to use continuous glucose monitoring based on their physician's medical judgment. * Patients with type 1 diabetes, age 20-69 years old * Currently receiving treatment with multiple insulin injection therapy * Patients who have access to KakaoTalk via smartphone and are able to communicate with it * Voluntarily agreed to participate in this clinical study.

Exclusion criteria

* Subjects using oral hypoglycemic agents * Steroid and immunosuppressant users * Subjects receiving anticancer medications * Breastfeeding or pregnant patients * Patients who do not voluntarily consent to the study * Anyone deemed unsuitable by the investigator to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Time In RangeWeek 6Derived from CGM

Secondary

MeasureTime frameDescription
Depressive symptomsWeek 6PHQ-9
Time In Tight RangeWeek 6Derived from CGM
Time Above RangeWeek 6Derived from CGM
Diabetes treatment satisfactionWeek 6DSTQ
Coefficient of VariationWeek 6Derived from CGM
Glycemic Management IndicatorWeek 6Derived from CGM
Time Below RangeWeek 6Derived from CGM

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026